ADMA Biologics Inc (ADMA)vsInsmed Inc (INSM)
ADMA
ADMA Biologics Inc
$9.63
-15.00%
HEALTHCARE · Cap: $2.29B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 19% more annual revenue ($606.42M vs $510.17M). ADMA leads profitability with a 28.8% profit margin vs -2.1%. ADMA earns a higher WallStSmart Score of 56/100 (C).
ADMA
Buy56
out of 100
Grade: C
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-299.0%
Fair Value
$4.08
Current Price
$9.63
$5.55 premium
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 36 in profit
Strong operational efficiency at 45.1%
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Attractively priced relative to earnings
18.4% revenue growth
No standout strengths identified
Areas to Watch
Earnings declined 52.8%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.8% and operating margin at 45.1%. Revenue growth of 18.4% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ADMA profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
ADMA is growing revenue faster at 18.4% — sustainability is the question.
ADMA generates stronger free cash flow (35M), providing more financial flexibility.
Bottom Line
ADMA scores higher overall (56/100 vs 39/100), backed by strong 28.8% margins and 18.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?